GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
+7.58%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.62B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
NVIDIA
NVDA
|
$390M |
| 2 |
Apple
AAPL
|
$374M |
| 3 |
Microsoft
MSFT
|
$322M |
| 4 |
Amazon
AMZN
|
$234M |
| 5 |
Meta Platforms (Facebook)
META
|
$194M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 45.53% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
576
Prime Medicine
PRME
$663M
| $7.88K | ﹤0.01% |
+2,700
| New | +$7.88K |
|
|
ALMS
577
Alumis Inc. Common Stock
ALMS
$479M
| $7.8K | ﹤0.01% |
+992
| New | +$7.8K |
|
578
Sana Biotechnology
SANA
$752M
| $7.64K | ﹤0.01% |
+4,688
| New | +$7.64K |
|
579
Taysha Gene Therapies
TSHA
$917M
| $7.44K | ﹤0.01% |
+4,303
| New | +$7.44K |
|
580
Y-mAbs Therapeutics
YMAB
$390M
| $7.36K | ﹤0.01% |
+940
| New | +$7.36K |
|
581
Design Therapeutics
DSGN
$367M
| $7.34K | ﹤0.01% |
+1,189
| New | +$7.34K |
|
|
PKST
582
Peakstone Realty Trust
PKST
$500M
| $7.26K | ﹤0.01% |
+656
| New | +$7.26K |
|
|
SVC
583
Service Properties Trust
SVC
$481M
| $7.22K | ﹤0.01% |
+2,842
| New | +$7.22K |
|
584
Corvus Pharmaceuticals
CRVS
$459M
| $7.22K | ﹤0.01% |
+1,349
| New | +$7.22K |
|
585
Neurogene
NGNE
$285M
| $7.13K | ﹤0.01% |
+312
| New | +$7.13K |
|
586
Olema Pharmaceuticals
OLMA
$570M
| $7.01K | ﹤0.01% |
+1,203
| New | +$7.01K |
|
|
DHC
587
Diversified Healthcare Trust
DHC
$995M
| $6.98K | ﹤0.01% |
+3,036
| New | +$6.98K |
|
|
SAGE
588
DELISTED
Sage Therapeutics
SAGE
| $6.97K | ﹤0.01% |
+1,284
| New | +$6.97K |
|
589
Tango Therapeutics
TNGX
$772M
| $6.97K | ﹤0.01% |
+2,255
| New | +$6.97K |
|
|
HPP
590
Hudson Pacific Properties
HPP
$1.16B
| $6.95K | ﹤0.01% |
+2,292
| New | +$6.95K |
|
591
Aquestive Therapeutics
AQST
$656M
| $6.81K | ﹤0.01% |
+1,914
| New | +$6.81K |
|
|
SLN
592
Silence Therapeutics
SLN
$269M
| $6.79K | ﹤0.01% |
+987
| New | +$6.79K |
|
|
RVNC
593
DELISTED
Revance Therapeutics, Inc.
RVNC
| $6.7K | ﹤0.01% |
+2,203
| New | +$6.7K |
|
|
LAND
594
Gladstone Land Corp
LAND
$325M
| $6.66K | ﹤0.01% |
+614
| New | +$6.66K |
|
595
Trevi Therapeutics
TRVI
$854M
| $6.65K | ﹤0.01% |
+1,614
| New | +$6.65K |
|
|
SLRN
596
DELISTED
ACELYRIN
SLRN
| $6.62K | ﹤0.01% |
+2,107
| New | +$6.62K |
|
|
CBL
597
CBL Properties
CBL
$990M
| $6.53K | ﹤0.01% |
+222
| New | +$6.53K |
|
598
Voyager Therapeutics
VYGR
$235M
| $6.5K | ﹤0.01% |
+1,147
| New | +$6.5K |
|
599
Absci
ABSI
$368M
| $6.32K | ﹤0.01% |
+2,412
| New | +$6.32K |
|
600
Rigel Pharmaceuticals
RIGL
$742M
| $6.22K | ﹤0.01% |
+370
| New | +$6.22K |
|